M.D. Anderson Researcher to Advise Evolv Health
DALLAS, TX (December 7, 2009) — Dr. Robert Newman, a renowned medical researcher and Professor Emeritus at The University of Texas M.D. Anderson Cancer Center in Houston, has agreed to consult with Health2o Products, LLC in regards to further testing of its Archaea Active™ formula.
Dr. Newman, currently Chief Science Officer (CSO) at a major New England nutraceutical company, will advise on future testing procedures and review and analyze test results from outside independent labs selected by Health2o.
Dr. Newman’s career has been dedicated to the development of novel therapeutic strategies to improve the quality of life for patients with inflammatory and malignant diseases. His research efforts are nationally-recognized, and have been accomplished through several scientific disciplines, including pharmacology, analytical chemistry, drug development and clinical pharmacology. His work has resulted in more than 300 peer-reviewed publications.
Dr. Newman recently retired from M.D. Anderson, following a 24-year career there and over 30 years in academic medicine. At M.D. Anderson, he served as the Founder and Co-Director of the Pharmaceutical Development Center. Dr. Newman obtained his M.S. and Ph.D degrees in Pharmacology and Toxicology from the University of Connecticut. He was a member of the University of Vermont Medical School for seven years and was later recruited to be head of the Section of Pharmacology at M.D. Anderson where was promoted to Professor in 1991 with tenure.
“We are very pleased that Dr. Newman has signed a consulting agreement with us to serve as a Senior Advisor. He will be assisting our company in developing a road map for the continuing research and analysis of our Archaea Active™ formula,” said Kevin D. Kuykendall, chairman and CEO of Health2o Products, LLC.